Funded Tech Companies
Windward Bio
Windward Bio, operating out of Basel, received equity investments through SR One Capital Management, Blue Owl Capital and OrbiMed.
Company Overview
Company Name
Windward Bio
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
Aeschenplatz 6
Basel, 4052
Switzerland
Basel, 4052
Switzerland
Phone
Website
Email Address
Company Background Information
Overview
Windward Bio is a clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committed to transforming the treatment of people living with serious immunological conditions. Its lead program is WIN378, a potential best-in-disease, ultra long-acting anti-TSLP monoclonal antibody currently in a Phase 2/3 trial for asthma. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bispecific with broad therapeutic potential across immunological diseases, which is currently in Phase 1. The company is building a discovery pipeline of long-acting bispecific antibodies, targeting validated biology in respiratory and dermatological conditions.
Last Transaction
5/4/2026
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Company Investors
- SR One Capital Management
- Blue Owl Capital
- OrbiMed (David Bonita)
- Sanofi Ventures
- Pivotal bioVenture Partners
- Harbour BioMed
- Omega Funds
- RA Capital Management
- Quan Capital
- Qiming Venture Partners USA
- RTW Investments
- Novo Holdings
- Janus Henderson Investors
Browse more funded tech companies:
Windstream | Windy Hill Medical
Share this article
About Our VC Transaction Database
This venture capital transaction data comes via a partnership with VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs








